文献速递神经肿瘤

伽玛刀放射外科治疗脑室内脑膜瘤的结局

Outcomes after gamma knife radiosurgery for intraventricular meningiomas.
PubMed 文献 · J Neurooncol · 2022-07-26

回顾性分析35年间19例患者20个脑室内脑膜瘤的伽玛刀放射外科治疗结局:中位随访63.1个月,症状控制率94.7%,5年和10年无进展生存率分别为95%和85%;V12Gy≥10 cc和肿瘤体积≥8 cc与瘤周水肿风险升高相关。作者认为伽玛刀是安全有效的管理选择,早期伽玛刀可考虑用于中小型脑室内脑膜瘤。

要点

  • 脑室内脑膜瘤伽玛刀治疗后5年无进展生存率95%,10年85%,症状控制率94.7%。
  • 诊断后12个月内行伽玛刀、未行活检直接伽玛刀及WHO I级者无进展生存期更长。
  • V12Gy≥10 cc或肿瘤体积≥8 cc者瘤周水肿风险升高。

核心结论

  • 伽玛刀放射外科是脑室内脑膜瘤安全有效的管理选择;作者认为早期伽玛刀可考虑作为中小型脑室内脑膜瘤的主要管理方式,并可作为残留脑室内脑膜瘤的辅助管理。

研究设计与样本

  • 回顾性复习美国匹兹堡大学医学中心35年间伽玛刀放射外科数据库,共2501例脑膜瘤,识别出19例患者(12例男性,平均年龄53.2岁,范围14-84岁)的20个脑室内脑膜瘤。

主要发现

  • 中位随访63.1个月(范围6-322.4个月),18例(94.7%)患者症状控制;总体无进展生存率5年为95%,10年为85%。
  • Log-rank检验显示诊断后12个月内行伽玛刀(对比≥12个月,X2:4.455,p=0.035)、未行活检直接伽玛刀(对比既往活检,X2:4.000,p=0.046)、WHO I级脑膜瘤(对比WHO II级,X2:9.000,p=0.003)者无进展生存期更长。
  • 7例在伽玛刀后中位10.5个月(范围6.13-24.3个月)出现影像学瘤周水肿,其中仅3例有症状并口服药物成功管理。
  • Cox回归显示V12Gy≥10 cc[HR:10.09(95%CI:2.11-48.21),p=0.004]和肿瘤体积≥8 cc[HR:5.87(95%CI:1.28-26.97),p=0.023]与瘤周水肿风险升高相关。

关键数值与推荐

  • 中位肿瘤体积4.8 cc(范围0.8-17 cc),中位边缘剂量14 Gy(范围12-25 Gy),处方于50%等剂量线。
  • 最常见症状为头痛(N=12),最常见位置为侧脑室三角区(N=18)。

临床怎么用

  • 作者认为伽玛刀是脑室内脑膜瘤安全有效的管理选择;早期伽玛刀可考虑作为中小型脑室内脑膜瘤的主要管理方式,并可作为残留脑室内脑膜瘤的辅助管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intraventricular meningiomas (IVMs) are rare tumors with considerable treatment-associated morbidity due to their challenging location. Treatment with stereotactic radiosurgery (SRS) is sparsely reported in the literature. We describe our experience over the last 35 years using Gamma knife radiosurgery (GKRS) for IVMs. METHODS: We retrospectively reviewed the GKRS database identifying 2501 meningiomas treated at the University of Pittsburgh Medical Center over the last 35 years. Nineteen patients with (12 males, mean age = 53.2 years, range 14-84) 20 IVMs were identified. Headache was the most frequent presenting symptom (N = 12), and the trigone of the lateral ventricle was the most common location (N = 18). The median tumor volume was 4.8 cc (range, 0.8-17). The median margin dose was 14 Gy (range, 12-25) delivered at 50% isodose line. RESULTS: At a median follow-up of 63.1 months (range, 6-322.4) symptom control was achieved in 18 (94.7%) patients. The overall progression-free survival (PFS) was 95% at 5 years, and 85% at 10-years. After Log-rank test, patients who underwent GKRS within 12 months after diagnosis (vs. ≥ 12 months, X2: 4.455, p = 0.035), patients treated with primary GKRS without prior biopsy (vs. prior biopsy, X2: 4.000, p = 0.046), and patients with WHO grade I meningioma (vs. WHO II, X2: 9.000, p = 0.003) had a longer PFS. Imaging showed peritumoral edema in seven cases at a median of 10.5 (range, 6.13-24.3) months after GKRS. Only three of these patients were symptomatic and were successfully managed with oral medications. Cox´s regression revealed that a V12Gy ≥ 10 cc [HR: 10.09 (95% CI: 2.11-48.21), p = 0.004], and tumor volume ≥ 8 cc [HR: 5.87 (95% CI: 1.28-26.97), p = 0.023] were associated with a higher risk of peritumoral edema. CONCLUSION: GKRS is an effective and safe management option for intraventricular meningiomas. Early GKRS should be considered as a primary management modality for small and medium sized IVM and adjuvant management for residual IVMs.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Daza-Ovalle A, Bin-Alamer O, Flickinger J, et al. Outcomes after gamma knife radiosurgery for intraventricular meningiomas. J Neurooncol. 2022. PMID: 35882752. doi:10.1007/s11060-022-04091-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。